Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-5 (of 5 Records) |
Query Trace: Streeter R[original query] |
---|
Finding optimal locations for implementing innovative hypertension management approaches among African American populations: Mapping barbershops, hair salons, and community health centers
Fujii Y , Streeter TE , Schieb L , Casper M , Wall HK . Prev Chronic Dis 2024 21 E10 |
Cuff size variation across manufacturers of home blood pressure devices: A current patient dilemma
Shahi S , Jackson SL , Streeter T , He S , Wall HK . Am J Hypertens 2023 36 (10) 532-535 BACKGROUND: The American Heart Association (AHA) recommends cuff sizes of blood pressure (BP) monitoring devices based on patient arm circumference, which is critical for accurate BP measurement. This study aimed to assess cuff size variation across validated BP devices and to examine the degree of alignment with the AHA recommendations. METHODS: Data on home-based BP devices were obtained from the US BP Validated Device Listing website and listed cuff sizes were compared against AHA recommendations: small adult (22-26cm), adult (27-34cm), large (35-44cm), and extra-large (XL) (45-52cm). RESULTS: There were 42 home-based validated BP devices from 13 manufacturers, and none offered cuffs that were aligned with the AHA recommendations. Over half of devices (22, 52.4%) were compatible with only a broad-range cuff, generally excluding arm sizes larger than 44cm. Only 5 devices from 4 manufacturers offered a cuff labeled "XL," and of these, only 3 devices had sizes that covered the AHA XL range. Terminology lacked consistency with manufacturers using: different labels to describe the same-sized cuffs (e.g., 22-42cm was labeled "integrated," "standard," "adult," "large," and "wide range"); the same labels to describe differently sized cuffs (e.g., cuffs labeled "large" were sized 22-42cm, 32-38cm, 32-42cm, 36-45cm). CONCLUSIONS: Manufacturers of US home BP devices employ inconsistent terminologies and thresholds for cuff sizes, and sizes were not aligned with AHA recommendations. This lack of standardization could pose challenges for clinicians and patients attempting to select a properly sized cuff to support hypertension diagnosis and management. |
Evaluation of the effects of wiping decontamination for filter cartridges of elastomeric half-mask respirators (EHMRs)
Vo E , Horvatin M , Zhuang Z , McClain C , Streeter R , Brannen J , Suhon NL . Am J Infect Control 2023 BACKGROUND: A major concern among healthcare experts is a shortage of N95 filtering facepiece respirators (FFRs) during a pandemic. If the supply of N95 FFRs becomes limited, reusable elastomeric half-mask respirators (EHMRs) may be used to protect healthcare workers. The focus of this study was to evaluate the effects on filter performance of wiping decontamination for EHMR P100 filter cartridges. METHODS: The filter cartridge exterior of EHMR Honeywell, Moldex, and MSA models was wiped using quaternary ammonium and sodium hypochlorite wipes. These filter cartridge properties were assessed including observational analysis and filter performance tests. These wiping and assessing procedures were repeated after each set of wiping cycles (50, 100, 150, 200, and 400 cycles) to determine the effects of wiping decontamination. RESULTS: For sodium hypochlorite wipes, Honeywell, Moldex, and MSA models passed the NIOSH liquid particulate penetration criteria for all wiping cycles from 50 to 400 (penetrations < 0.014%). For quaternary ammonium wipes, filter penetrations of Moldex failed (penetrations >0.03%) after 150 cycles, while the filter penetrations of Honeywell and MSA passed for all wiping cycles (penetrations ≤ 0.013%). CONCLUSIONS: Wiping decontamination methods using sodium hypochlorite and quaternary ammonium wipes could be considered as promising decontamination candidates for Honeywell, Moldex, and MSA reuse, except for the wiping number selection for Moldex (< 150 cycles) when using the quaternary ammonium wipe. |
An opportunity to better address hypertension in women: Self-measured blood pressure monitoring
Wall HK , Streeter TE , Wright JS . J Womens Health (Larchmt) 2022 31 (10) 1380-1386 More than 56 million women in the United States have hypertension, including almost one in five women of reproductive age. The prevalence of hypertensive disorders of pregnancy is on the rise, putting more women at risk for adverse pregnancy-related outcomes and atherosclerotic cardiovascular disease later in life. Hypertension can be better detected and controlled in women throughout their life course by supporting self-measured blood pressure monitoring. In this study, we present some potential strategies for strengthening our nation's ability to address hypertension in women focusing on pregnancy-related considerations for self-measured blood pressure monitoring. |
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
Sun W , Patel A , Normolle D , Patel K , Ohr J , Lee JJ , Bahary N , Chu E , Streeter N , Drummond S . Cancer 2018 125 (6) 902-909 BACKGROUND: Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. METHODS: In this single arm-study, patients with advanced/unresectable or metastatic biliary tract cancer who failed at least 1 line of systemic chemotherapy received regorafenib once daily on a schedule of 21-days on/7-days off in a 28-day cycle. Patients initially received a standard 160 mg dose. After toxicity assessments in the first 3 patients, the dose was reduced to 120 mg for subsequent patients, as preplanned. The primary endpoint was progression-free survival (PFS). Secondary objectives included overall survival (OS), the objective response rate, and the disease control rate. RESULTS: Forty-three patients received at least 1 dose of regorafenib, and 34 patients who received at least 1 cycle of treatment were evaluable for tumor response. The median PFS was 15.6 weeks (90% confidence interval, 12.9-24.7 weeks), and the median OS was 31.8 weeks (90% confidence interval, 13.3-74.3 weeks), with survival rates 40% at 12 months and 32% at 18 months. A partial response was achieved in 5 patients (11%), and 19 had stable disease (44%), for a disease control rate of 56%. The toxicity profile was as expected, with grade 3 and 4 adverse events reported in 40% of patients. The most common toxicities were hypophosphatemia (40%), hyperbilirubinemia (26%), hypertension (23%), and hand-foot skin reaction (7%). CONCLUSIONS: The current results suggest promising efficacy of regorafenib in patients with chemotherapy-refractory, advanced/metastatic biliary tract cancer, warranting further studies to confirm its clinical efficacy. There is a clear unmet need for effective therapies in patients who have advanced and metastatic biliary tract cancer. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure